Schroeckenfuchs has been in his current role since 2022, before which he had been the president for the Middle East and Head of Novartis’ MENA Cluster since 2018. In June 2024, at the BIO 2024 International Convention, the company signed an MoU with the Department of Health – Abu Dhabi to advance clinical genomics research to support the understanding of radioligand therapy for cancer patients. Schroeckenfuchs is a member of the Asia Pacific Middle East Africa (APMA) leadership team. He started his career with Novartis in 2001 as head of general medicine in Austria.